Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +1.32
Percentage change 8.55	%

Peers: FENC AKBA EOLS ARDX ESPR PDSB KNSA ACXP CRVS ATHE

| Held by: IWM VTI VXF IWN IBB SCHA VTWO IWC IWO SBIO

Index	RUT	P/E	-	EPS (ttm)	-3.64	Insider Own	50.62%	Shs Outstand	49.82M	Perf Week	27.77%
Market Cap	1.05B	Forward P/E	-	EPS next Y	-3.96	Insider Trans	8.21%	Shs Float	31.00M	Perf Month	74.48%
Income	-177.81M	PEG	-	EPS next Q	-1.03	Inst Own	43.39%	Short Float	6.50%	Perf Quarter	40.76%
Sales	0.00M	P/S	-	EPS this Y	-6.33%	Inst Trans	6.36%	Short Ratio	2.55	Perf Half Y	44.40%
Book/sh	3.84	P/B	4.36	EPS next Y	-1.88%	ROA	-77.72%	Short Interest	2.01M	Perf Year	31.99%
Cash/sh	3.16	P/C	5.31	EPS next 5Y	-3.06%	ROE	-82.24%	52W Range	8.24 - 18.29	Perf YTD	36.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-170.42%	ROI	-92.97%	52W High	-8.42%	Beta	-0.35
Dividend TTM	-	Quick Ratio	14.02	Sales past 5Y	0.00%	Gross Margin	-	52W Low	103.25%	ATR (14)	1.44
Dividend Ex-Date	-	Current Ratio	14.02	EPS Y/Y TTM	-106.10%	Oper. Margin	-	RSI (14)	74.69	Volatility	9.88% 10.53%
Employees	51	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	36.71
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-61.06%	Payout	-	Rel Volume	3.03	Prev Close	15.43
Sales Surprise	-	EPS Surprise	9.01%	Sales Q/Q	-	Earnings	Feb 12 BMO	Avg Volume	790.54K	Price	16.75
SMA20	44.19%	SMA50	55.99%	SMA200	38.23%	Trades		Volume	2,285,010	Change	8.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Mar-18-25 07:58PM	Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) +8.51% +8.55%
04:01PM	Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire)
Mar-17-25 08:00AM	Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo (GlobeNewswire)
Mar-11-25 10:20PM	Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.32%
Mar-10-25 04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +42.21%
01:50PM	Loading…
01:50PM	Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate (Benzinga)
12:57PM	Mineralyss stock soars as hypertension pill scores in two pivotal trials (Clinical Trials Arena)
07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension (GlobeNewswire)
06:30AM	Mineralys shares climb on study data for blood pressure drug (BioPharma Dive)
Mar-07-25 04:01PM	Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET (GlobeNewswire)
Feb-13-25 02:19AM	Q4 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:10AM	Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ... (GuruFocus.com)
Feb-12-25 07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.04%
Feb-05-25 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 (GlobeNewswire)
Feb-04-25 08:00AM	Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria (GlobeNewswire)
08:29AM	Loading…
Jan-09-25 08:29AM	Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials (TipRanks)
Jan-08-25 08:00AM	Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension (GlobeNewswire) -13.71%
Nov-12-24 11:00PM	Mineralys Therapeutics Announces Q3 2024 Results and Updates (TipRanks) -10.32% -6.95%
10:12AM	Q3 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-11-24 04:05PM	Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +6.27%
Nov-05-24 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.66%
Nov-04-24 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 (GlobeNewswire)
Oct-30-24 08:00AM	Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)
Sep-25-24 08:00AM	Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Aug-28-24 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-24 04:05PM	Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -22.82%
Aug-05-24 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 (GlobeNewswire) -5.66%
Jul-12-24 07:01PM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares (GuruFocus.com) +6.71%
07:01PM	Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares (GuruFocus.com)
03:11AM	Loading…
Jun-21-24 03:11AM	Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-15-24 02:53AM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares (GuruFocus.com)
Jun-14-24 08:00AM	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors (GlobeNewswire)
02:43AM	Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-03-24 08:00AM	Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-13-24 11:45AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:56AM	MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire) +6.18%
May-02-24 08:00AM	Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 (GlobeNewswire)
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-22-24 10:51AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:53AM	MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... (GuruFocus.com)
07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-13-24 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 (GlobeNewswire)
Feb-08-24 08:00AM	Mineralys Therapeutics Announces $120 Million Private Placement Financing (GlobeNewswire) +12.51%
Jan-29-24 04:05PM	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference (GlobeNewswire) +6.21%
Jan-17-24 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-04-24 04:05PM	Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer (GlobeNewswire)
Dec-21-23 04:05PM	Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire) +8.30%
Nov-12-23 09:22AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-11-23 11:30AM	Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 (GlobeNewswire)
Nov-09-23 04:05PM	Mineralys Therapeutics to Participate in Three Upcoming Conferences (GlobeNewswire) -9.31% -12.84%
Nov-07-23 05:12PM	Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ... (GuruFocus.com) +8.02% -6.74%
04:05PM	Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 10:00AM	Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting (GlobeNewswire)
Oct-31-23 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023 (GlobeNewswire)
Oct-13-23 04:10PM	Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 (GlobeNewswire) +5.59% +5.19%
Sep-19-23 04:00PM	Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy (GlobeNewswire)
Sep-14-23 04:05PM	Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas (GlobeNewswire)
Sep-11-23 04:05PM	Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023 (GlobeNewswire)
Sep-10-23 07:47AM	Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension (GlobeNewswire)
07:45AM	Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire)
Sep-09-23 05:00AM	CEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Sep-05-23 04:05PM	Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire) -5.57%
09:55AM	Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High? (Zacks)
Aug-29-23 04:05PM	Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 (GlobeNewswire)
Aug-22-23 05:45PM	Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.84%
Aug-07-23 04:05PM	Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.02% +6.96%
Jul-31-23 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023 (GlobeNewswire)
Jul-17-23 04:01PM	Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD) (GlobeNewswire)
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-31-23 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-15-23 04:01PM	Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-23 08:39AM	We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth (Simply Wall St.)
May-02-23 08:00AM	Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension (GlobeNewswire)
May-01-23 08:00AM	Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023 (GlobeNewswire)
Apr-27-23 04:47PM	Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023 (GlobeNewswire)
Mar-15-23 04:01PM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Mar-04-23 04:30PM	Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC (GlobeNewswire)
Mar-01-23 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023 (GlobeNewswire)
Feb-20-23 08:00AM	Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023 (GlobeNewswire)
Feb-17-23 12:08PM	Lab Notes: AnPac dips into real estate with diversification strategy; Mineralys closes $220.8M IPO (American City Business Journals)
Feb-14-23 04:01PM	Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-23 05:16PM	Mineralys, Enlight Trading Debuts Add to Big Week for US IPOs (Bloomberg)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Samsara BioCapital GP, LLC	10% Owner	Mar 13 '25	Buy	13.50	600,000	8,100,000	5,674,916	Mar 17 09:05 PM
AKKARAJU SRINIVAS	Director	Mar 13 '25	Buy	13.50	600,000	8,100,000	5,674,916	Mar 17 09:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 13 '25	Buy	13.50	1,296,296	17,499,996	4,280,051	Mar 17 07:56 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '25	Option Exercise	1.08	6,349	6,857	170,869	Mar 13 05:15 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '25	Option Exercise	1.08	6,348	6,856	164,520	Feb 13 05:29 PM
Levy Adam Scott	CFO and Secretary	Jan 13 '25	Sale	9.10	10,757	97,864	226,097	Jan 15 09:46 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '25	Option Exercise	0.84	11,367	9,567	158,172	Jan 15 09:45 PM
Congleton Jon	Chief Executive Officer	Jan 13 '25	Sale	9.06	18,333	166,082	877,608	Jan 15 09:44 PM
Congleton Jon	Officer	Jan 13 '25	Proposed Sale	9.06	18,333	166,083		Jan 13 06:34 PM
Levy Adam Scott	Officer	Jan 13 '25	Proposed Sale	9.10	10,757	97,864		Jan 13 06:21 PM
Rodman David Malcom	Chief Medical Officer	Dec 11 '24	Option Exercise	0.54	5,017	2,709	146,008	Dec 13 04:37 PM
Rodman David Malcom	Chief Medical Officer	Nov 11 '24	Option Exercise	0.81	10,043	8,137	146,017	Nov 12 05:25 PM
Rodman David Malcom	Chief Medical Officer	Nov 11 '24	Sale	15.00	5,026	75,398	140,991	Nov 12 05:25 PM
Rodman David Malcom	Officer	Nov 11 '24	Proposed Sale	15.00	5,026	75,398		Nov 12 10:40 AM
Rodman David Malcom	Chief Medical Officer	Nov 06 '24	Option Exercise	1.08	25,482	27,521	161,456	Nov 08 04:21 PM
Rodman David Malcom	Chief Medical Officer	Nov 06 '24	Sale	15.03	25,482	383,066	135,974	Nov 08 04:21 PM
Rodman David Malcom	Officer	Nov 06 '24	Proposed Sale	15.03	25,482	383,067		Nov 06 06:43 PM
Levy Adam Scott	CFO and Secretary	Oct 11 '24	Sale	13.57	10,757	146,004	236,854	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 14 '24	Option Exercise	1.08	5,352	5,780	135,974	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 11 '24	Option Exercise	0.54	5,017	2,709	130,622	Oct 15 04:22 PM
Congleton Jon	Chief Executive Officer	Oct 11 '24	Sale	13.52	15,271	206,433	895,941	Oct 15 04:21 PM
Congleton Jon	Officer	Oct 11 '24	Proposed Sale	13.52	15,271	206,434		Oct 11 04:54 PM
Levy Adam Scott	Officer	Oct 11 '24	Proposed Sale	13.57	10,757	146,004		Oct 11 04:48 PM
Rodman David Malcom	Chief Medical Officer	Sep 12 '24	Option Exercise	1.08	6,349	6,857	125,605	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Sep 11 '24	Option Exercise	0.54	5,018	2,710	119,256	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Aug 12 '24	Option Exercise	0.84	11,365	9,565	114,238	Aug 13 04:20 PM
Slingsby Brian Taylor	Director	Jul 24 '24	Sale	13.05	550,000	7,177,500	8,644,579	Jul 26 09:45 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Option Exercise	1.08	525	567	103,398	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Sale	15.00	525	7,876	102,873	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 12 '24	Option Exercise	1.08	6,349	6,857	102,873	Jul 12 04:39 PM
Rodman David Malcom	Chief Medical Officer	Jul 11 '24	Option Exercise	0.54	5,017	2,709	96,524	Jul 12 04:39 PM
Levy Adam Scott	CFO and Secretary	Jul 11 '24	Sale	13.14	10,757	141,394	247,611	Jul 12 04:37 PM
Congleton Jon	Chief Executive Officer	Jul 11 '24	Sale	13.34	15,746	210,075	911,212	Jul 12 04:36 PM
Congleton Jon	Chief Executive Officer	Jun 17 '24	Sale	12.25	17,766	217,712	958,505	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 18 '24	Sale	11.99	16,607	199,073	941,898	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 20 '24	Sale	11.73	14,940	175,237	926,958	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 13 '24	Sale	12.74	39,961	509,027	992,500	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 12 '24	Sale	12.77	16,607	212,013	1,032,461	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 14 '24	Sale	12.52	16,229	203,163	976,271	Jun 14 06:15 PM
Levy Adam Scott	CFO and Secretary	Jun 11 '24	Sale	12.94	96,815	1,252,718	255,462	Jun 13 05:33 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '24	Option Exercise	1.08	6,349	6,857	89,729	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	Jun 11 '24	Option Exercise	0.54	5,017	2,709	83,380	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	May 13 '24	Option Exercise	0.84	11,366	9,566	78,363	May 15 04:43 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Option Exercise	1.08	100	108	67,097	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Sale	15.00	100	1,500	66,997	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 12 '24	Option Exercise	1.08	6,349	6,857	66,997	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Apr 11 '24	Option Exercise	0.54	5,017	2,709	60,648	Apr 15 04:24 PM

Dollar change +0.09
Percentage change 0.27	%

SRRK Scholar Rock Holding Corp daily Stock Chart

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE CARA

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.57	Insider Own	23.16%	Shs Outstand	93.82M	Perf Week	-5.09%
Market Cap	3.22B	Forward P/E	-	EPS next Y	-1.21	Insider Trans	-15.10%	Shs Float	72.75M	Perf Month	-8.06%
Income	-246.29M	PEG	-	EPS next Q	-0.66	Inst Own	94.21%	Short Float	21.93%	Perf Quarter	-19.08%
Sales	0.00M	P/S	-	EPS this Y	5.17%	Inst Trans	25.86%	Short Ratio	17.11	Perf Half Y	319.38%
Book/sh	3.93	P/B	8.65	EPS next Y	48.50%	ROA	-62.67%	Short Interest	15.95M	Perf Year	135.09%
Cash/sh	4.62	P/C	7.35	EPS next 5Y	-	ROE	-82.95%	52W Range	6.76 - 46.98	Perf YTD	-21.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.90%	ROI	-57.55%	52W High	-27.69%	Beta	0.54
Dividend TTM	-	Quick Ratio	9.61	Sales past 5Y	-5.25%	Gross Margin	-	52W Low	402.51%	ATR (14)	2.04
Dividend Ex-Date	-	Current Ratio	9.61	EPS Y/Y TTM	-22.34%	Oper. Margin	-	RSI (14)	37.92	Volatility	4.82% 5.82%
Employees	196	Debt/Eq	0.18	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	50.50
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	-16.67%	Payout	-	Rel Volume	0.98	Prev Close	33.88
Sales Surprise	-	EPS Surprise	-3.13%	Sales Q/Q	-	Earnings	Feb 27 BMO	Avg Volume	932.08K	Price	33.97
SMA20	-5.76%	SMA50	-13.11%	SMA200	39.50%	Trades		Volume	913,392	Change	0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59
Mar-12-20	Initiated	Robert W. Baird	Outperform	$35

Show Previous Ratings

Mar-17-25 08:31AM	Scholar Rock SMA drug shows muscle function benefit (Clinical Trials Arena)
Mar-16-25 07:00PM	Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Mar-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 11:16PM	Q4 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents) +7.95%
07:00AM	Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress (Business Wire)
07:24AM	Loading…
Feb-26-25 07:24AM	Earnings To Watch: Scholar Rock Holding Corp (SRRK) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 04:15PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-25 01:10PM	Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now? (Insider Monkey)
Feb-21-25 08:00AM	Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Feb-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025 (Business Wire)
Jan-29-25 08:05AM	Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
08:00AM	Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition (Business Wire)
Jan-17-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 06:48PM	Heres Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing (Insider Monkey) +5.21%
04:00PM	Loading…
Jan-08-25 04:00PM	Scholar Rock Highlights 2025 Strategic Priorities (Business Wire)
Jan-02-25 08:00AM	Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-04-24 12:36PM	Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%
06:13AM	Biohaven muscle drug misses goal of SMA study, but advances in obesity (BioPharma Dive)
Nov-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 02:08AM	Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 07:00AM	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Business Wire) -5.29%
Nov-11-24 07:07AM	Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Business Wire)
Nov-01-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Business Wire)
Oct-31-24 04:00PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire) -5.14%
08:00AM	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Business Wire)
Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
09:55AM	Loading…
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%
05:38AM	Here's Why Everybody's Talking About Scholar Rock Right Now (Motley Fool)
Oct-08-24 11:08PM	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -13.97%
08:29AM	Scholar Rocks SMA Treatment Trials Show Promising Results (TipRanks)
06:43AM	Scholar Rock stocks skyrocket after SMA drug scores at Phase III (Clinical Trials Arena)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +361.99%
04:09PM	Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
03:23PM	Scholar Rock Shares Quadruple On Positive Drug-Study Results (The Wall Street Journal)
11:05AM	Scholar Rock stock surges on positive spinal muscular atrophy treatment data (Investing.com)
11:05AM	Scholar Rock Stock Quadruples on Positive Trial Data (Barrons.com)
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
07:00AM	Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-27-24 06:13AM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now (Insider Monkey)
Sep-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.48%
Sep-10-24 08:00AM	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Business Wire) +5.89%
Sep-05-24 12:02AM	Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-04-24 08:00AM	Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer (Business Wire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Aug-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-15-24 04:32AM	Scholar Rocks apitegromab shows promise for non-ambulatory SMA (Clinical Trials Arena)
Aug-09-24 05:05AM	Q2 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-24 07:00AM	Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Jul-23-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Business Wire)
Jul-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-08-24 06:42PM	Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 07:00AM	Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal (Business Wire)
Jun-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 04:00PM	Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting (Business Wire)
May-28-24 08:00AM	Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-22-24 07:00AM	Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity (Business Wire)
May-20-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
May-17-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.78%
May-14-24 08:00AM	Scholar Rock to Host Investor Day on May 22, 2024 (Business Wire)
May-07-24 01:53PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024 (InvestorPlace)
10:19AM	Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss (MT Newswires)
08:52AM	Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
07:00AM	Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Apr-24-24 06:33AM	3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains (InvestorPlace)
Apr-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.08%
Mar-20-24 05:31AM	Scholar Rock Holding Corp Reports Full Year 2023 Financial Results (GuruFocus.com) +8.58%
Mar-19-24 10:52PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023 (InvestorPlace) +14.77%
07:00AM	Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress (Business Wire)
Mar-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.65%
08:18AM	Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks (Insider Monkey)
Feb-28-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.42%
Feb-15-24 08:00AM	Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer (Business Wire)
Feb-06-24 08:00AM	Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management (Business Wire)
Jan-25-24 08:00AM	Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia (Business Wire)
Jan-23-24 08:00AM	Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity (Business Wire)
Jan-22-24 07:00AM	Obesity Drugs Lead to Muscle LossPharma Companies Want to Fix That (The Wall Street Journal)
Jan-18-24 05:01PM	Insider Edward Myles Sells 6,634 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com) -5.10%
Jan-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 08:00AM	Scholar Rock Provides Corporate Update and Highlights Priorities for 2024 (Business Wire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace) -6.91%
Dec-30-23 07:01PM	Insider Edward Myles Sells 12,459 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Dec-19-23 08:00AM	Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +5.29%
Dec-15-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Dec-10-23 09:05AM	Insider Sell: COO & CFO Edward Myles Sells 24,914 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Nov-17-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-23 12:32PM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:14AM	Scholar Rock Holding Corp (SRRK) Reports Q3 2023 Financial Results (GuruFocus.com)
07:15AM	Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress (Business Wire)
Nov-06-23 09:55AM	Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High? (Zacks)
Nov-03-23 11:52PM	Insider Sell: Edward Myles Sells 35,007 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Peng Katie	Director	Mar 17 '25	Sale	34.42	1,006	34,627	30,319	Mar 19 05:00 PM
Katie Peng	Director	Mar 17 '25	Proposed Sale	34.60	4,037	139,680		Mar 17 06:50 PM
Myles Edward H	COO & CFO	Mar 10 '25	Option Exercise	13.60	112,897	1,535,083	253,637	Mar 12 07:06 PM
Myles Edward H	COO & CFO	Mar 10 '25	Sale	35.62	142,292	5,068,974	111,345	Mar 12 07:06 PM
Edward Myles	Officer	Mar 10 '25	Proposed Sale	35.00	161,890	5,666,150		Mar 10 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Option Exercise	10.19	48,308	492,186	179,594	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Sale	37.40	68,510	2,562,479	111,084	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	36.83	4,135	152,288	131,286	Feb 20 07:55 PM
Parlavecchio Caryn	CHRO	Feb 18 '25	Sale	36.83	5,296	195,046	140,258	Feb 20 06:30 PM
Myles Edward H	COO & CFO	Feb 18 '25	Sale	36.83	7,809	287,598	140,740	Feb 20 06:18 PM
Ho Junlin	GENERAL COUNSEL	Feb 18 '25	Sale	36.83	5,742	211,472	189,295	Feb 20 05:53 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	36.83	18,372	676,622	311,991	Feb 20 05:41 PM
Mohammed Qatanani	Officer	Feb 19 '25	Proposed Sale	36.95	68,510	2,531,444		Feb 19 04:15 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Jan 16 '25	Sale	44.20	22,308	985,951	330,363	Jan 21 04:35 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '25	Sale	44.20	5,655	249,935	67,200	Jan 21 04:35 PM
Sacco Tracey	Chief Commercial Officer	Jan 16 '25	Sale	44.20	3,890	171,927	45,395	Jan 21 04:35 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '25	Sale	44.20	7,347	324,717	135,421	Jan 21 04:35 PM
Parlavecchio Caryn	CHRO	Jan 16 '25	Sale	44.20	6,434	284,365	145,554	Jan 21 04:35 PM
Myles Edward H	COO & CFO	Jan 16 '25	Sale	44.20	12,539	554,189	148,549	Jan 21 04:35 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '25	Sale	44.20	9,039	399,498	195,037	Jan 21 04:35 PM
Invus Public Equities, L.P.	10% Owner	Dec 10 '24	Sale	41.65	1,600,000	66,640,000	9,250,005	Dec 12 04:39 PM
Invus Public Equities, L.P.	10% Owner	Nov 25 '24	Sale	38.49	409,433	15,757,639	10,850,005	Nov 27 04:31 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Option Exercise	8.59	6,375	54,761	79,230	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Option Exercise	8.59	2,145	18,426	75,000	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Sale	39.44	6,375	251,399	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Sale	30.01	2,145	64,372	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Option Exercise	8.59	2,105	18,082	74,960	Nov 13 04:40 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Sale	30.00	2,105	63,158	72,855	Nov 13 04:40 PM
Myles Edward H	COO & CFO	Oct 08 '24	Option Exercise	10.00	37,187	371,870	198,275	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 08 '24	Sale	34.90	37,187	1,297,659	161,088	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 07 '24	Sale	26.56	206,240	5,477,546	161,088	Oct 07 09:52 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Option Exercise	10.00	30,000	300,000	79,285	Oct 07 09:03 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Sale	25.62	30,000	768,677	49,285	Oct 07 09:03 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Sale	29.25	1,175,713	34,385,672	5,612,896	Oct 07 08:55 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Option Exercise	8.59	109,375	939,531	182,230	Oct 07 08:51 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Sale	27.21	109,375	2,976,468	72,855	Oct 07 08:51 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Proposed Sale	29.25	1,175,713	34,385,725		Oct 07 08:43 PM
Tracey Sacco	Officer	Oct 07 '24	Proposed Sale	25.62	30,000	768,693		Oct 07 04:20 PM
Jing Marantz	Officer	Oct 07 '24	Proposed Sale	32.50	120,000	3,900,000		Oct 07 04:18 PM
Edward Myles	Officer	Oct 07 '24	Proposed Sale	32.50	243,427	7,911,378		Oct 07 04:16 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '24	Sale	8.58	1,936	16,611	142,768	Sep 19 08:15 AM
Parlavecchio Caryn	CHRO	Aug 16 '24	Sale	9.33	1,451	13,538	151,988	Aug 19 05:00 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 17 '24	Sale	8.98	2,315	20,800	144,704	Jun 18 05:56 PM
Parlavecchio Caryn	CHRO	Jun 17 '24	Sale	8.98	4,305	38,680	153,439	Jun 18 05:55 PM
Myles Edward H	COO & CFO	Jun 17 '24	Sale	8.98	9,458	84,978	201,518	Jun 18 05:54 PM
Ho Junlin	GENERAL COUNSEL	Jun 17 '24	Sale	8.98	4,695	42,183	204,076	Jun 18 05:53 PM

Open in Screener

ALMS

Alumis Inc

Mar 19 • 04:00PM ET

4.37

Dollar change -0.11
Percentage change -2.46	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA INCY BMY ABBV PFE

| Held by: VTI IWM VXF IBB IWO VTWO SCHA IWN IWC SCHB

Index	RUT	P/E	-	EPS (ttm)	-4.47	Insider Own	53.59%	Shs Outstand	47.22M	Perf Week	-12.60%
Market Cap	237.76M	Forward P/E	-	EPS next Y	-3.71	Insider Trans	0.00%	Shs Float	25.25M	Perf Month	-13.64%
Income	-238.77M	PEG	-	EPS next Q	-1.25	Inst Own	34.73%	Short Float	11.63%	Perf Quarter	-47.91%
Sales	0.00M	P/S	-	EPS this Y	42.59%	Inst Trans	48.29%	Short Ratio	15.31	Perf Half Y	-60.45%
Book/sh	6.40	P/B	0.68	EPS next Y	6.89%	ROA	-	Short Interest	2.94M	Perf Year	-
Cash/sh	6.65	P/C	0.66	EPS next 5Y	11.58%	ROE	-	52W Range	4.25 - 13.53	Perf YTD	-44.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-63.16%	52W High	-67.70%	Beta	-
Dividend TTM	-	Quick Ratio	11.26	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.82%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	11.26	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	35.25	Volatility	9.16% 8.81%
Employees	-	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.20	Target Price	21.75
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	-104.55%	Payout	-	Rel Volume	0.72	Prev Close	4.48
Sales Surprise	-	EPS Surprise	-24.70%	Sales Q/Q	-	Earnings	Mar 19 AMC	Avg Volume	191.83K	Price	4.37
SMA20	-8.09%	SMA50	-26.16%	SMA200	-54.64%	Trades		Volume	139,721	Change	-2.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Initiated	Oppenheimer	Outperform	$32
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Mar-19-25 04:05PM	Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Mar-10-25 08:00AM	Alumis to Present at Leerink's 2025 Global Healthcare Conference (GlobeNewswire)
Mar-08-25 09:00AM	Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis (GlobeNewswire)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	Loading…
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
Feb-28-25 09:08AM	Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout (GlobeNewswire)
Feb-27-25 04:15PM	Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases (GlobeNewswire)
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-10-25 04:45PM	Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -14.99%
Feb-07-25 10:44AM	Alumis and Acelyrin sign merger agreement (Pharmaceutical Technology) -13.96%
03:00AM	Immune drugmakers Alumis and Acelyrin to merge (BioPharma Dive)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) -7.57%
Jan-30-25 02:48PM	Why Alumis (ALMS) Stock Is Advancing Today (Insider Monkey)
Jan-28-25 08:00AM	Alumis Strengthens Leadership Team with Key Appointments (GlobeNewswire)
08:00AM	Loading…
Dec-19-24 08:00AM	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 (GlobeNewswire)
Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Labs, LLC	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:31 PM
Foresite Capital Management V,	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM
Tananbaum James B.	Director	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM

Open in Screener

SYRS

Syros Pharmaceuticals Inc

Mar 19 • 04:00PM ET

0.1172

Dollar change -0.0108
Percentage change -8.44	%

Healthcare • Biotechnology • USA • NASD

SYRS Syros Pharmaceuticals Inc daily Stock Chart

Peers: VRTX BMRN BLUE RGEN IONS CRSP NTLA EDIT FATE SGMO

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-3.03	Insider Own	11.80%	Shs Outstand	26.83M	Perf Week	39.19%
Market Cap	3.14M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	-14.57%	Shs Float	23.67M	Perf Month	-40.27%
Income	-97.81M	PEG	-	EPS next Q	-0.65	Inst Own	8.27%	Short Float	3.97%	Perf Quarter	-43.44%
Sales	0.39M	P/S	8.05	EPS this Y	74.11%	Inst Trans	-83.49%	Short Ratio	0.04	Perf Half Y	-94.08%
Book/sh	-0.41	P/B	-	EPS next Y	36.71%	ROA	-84.04%	Short Interest	0.94M	Perf Year	-98.05%
Cash/sh	2.17	P/C	0.05	EPS next 5Y	52.99%	ROE	-776.96%	52W Range	0.07 - 6.93	Perf YTD	-49.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.16%	ROI	-210.27%	52W High	-98.31%	Beta	1.57
Dividend TTM	-	Quick Ratio	2.25	Sales past 5Y	161.81%	Gross Margin	-228.76%	52W Low	79.48%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	2.25	EPS Y/Y TTM	19.37%	Oper. Margin	-28892.23%	RSI (14)	46.40	Volatility	39.54% 27.91%
Employees	68	Debt/Eq	-	Sales Y/Y TTM	-95.61%	Profit Margin	-25340.67%	Recom	2.00	Target Price	20.00
Option/Short	Yes / No	LT Debt/Eq	-	EPS Q/Q	88.66%	Payout	-	Rel Volume	0.59	Prev Close	0.13
Sales Surprise	-100.00%	EPS Surprise	76.34%	Sales Q/Q	-100.00%	Earnings	Oct 31 BMO	Avg Volume	24.28M	Price	0.12
SMA20	-0.14%	SMA50	-29.34%	SMA200	-94.48%	Trades		Volume	14,991,631	Change	-8.44%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-20	Upgrade	H.C. Wainwright	Neutral → Buy	$11 → $15
Sep-22-20	Initiated	Alliance Global Partners	Buy	$18
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Mar-08-19	Resumed	JMP Securities	Mkt Outperform	$18
Feb-14-19	Resumed	Oppenheimer	Outperform	$13
Nov-05-18	Upgrade	ROTH Capital	Neutral → Buy
Mar-13-18	Reiterated	Wedbush	Outperform	$11 → $13
Oct-31-17	Resumed	Piper Jaffray	Overweight	$30
Oct-23-17	Initiated	ROTH Capital	Neutral	$15
Aug-10-17	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Feb-28-25 04:05PM	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration (Business Wire) -42.74%
Feb-18-25 02:29AM	'We are back' Greek shipyards say after decades of pain (Reuters) +6.05%
Jan-20-25 07:23AM	Kia starts series production of Syros in India (Just Auto)
Jan-07-25 04:58AM	South Africas Westfalia Fruit acquires Belgian avocado products maker Syros (Just Food) -10.25%
Dec-20-24 06:59AM	Kia launches Syros compact SUV in India (Just Auto)
06:35AM	Loading…
Nov-14-24 06:35AM	Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright (TipRanks) -23.37%
Nov-13-24 07:27AM	Syros stock craters after lead cancer therapy flops in Phase III trial (Clinical Trials Arena) -86.85%
Nov-12-24 04:30PM	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression (Business Wire) -15.48%
Nov-01-24 09:00AM	Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... (GuruFocus.com) -10.12%
Oct-31-24 07:30AM	Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Oct-24-24 07:08AM	Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 (Business Wire) -8.00%
Oct-09-24 03:33PM	Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... (GuruFocus.com)
Sep-12-24 07:00PM	Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com) +24.20%
07:00PM	Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com)
Aug-27-24 07:00AM	Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences (Business Wire) -5.99%
10:19AM	Loading…
Aug-14-24 10:19AM	Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination (Zacks) -15.89%
09:35AM	Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-13-24 09:41AM	Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome (Benzinga) -61.68%
09:13AM	Syros stock craters after Phase II AML trial termination due to inefficacy (Pharmaceutical Technology)
Aug-12-24 04:15PM	Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial (Business Wire)
Aug-05-24 09:55AM	Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:30AM	Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Jul-24-24 07:00AM	Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 (Business Wire)
Jul-17-24 11:24AM	Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why (Zacks)
08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-13-24 07:00AM	Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression (Business Wire) +7.41%
May-15-24 03:03AM	Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
01:14AM	Q1 2024 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 10:52AM	SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +7.31%
07:30AM	Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
09:00AM	Loading…
May-07-24 09:00AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
07:00AM	Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 (Business Wire)
May-01-24 10:01AM	Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-24 09:49AM	Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML (Zacks)
08:30AM	Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-09-24 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression (Business Wire) +22.22%
Apr-02-24 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.04% +7.44%
Mar-28-24 10:06AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.39%
Mar-27-24 11:53AM	SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.56%
07:30AM	Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Mar-25-24 07:00AM	Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial (Business Wire)
Mar-20-24 07:00AM	Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 (Business Wire)
Feb-27-24 07:00AM	Syros to Participate in TD Cowen 44th Annual Health Care Conference (Business Wire)
Jan-31-24 04:00PM	3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential (InvestorPlace)
Jan-19-24 10:43AM	Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why (Zacks)
Jan-18-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice (Zacks) -6.09%
Jan-17-24 08:50AM	Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-16-24 12:00PM	What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know (Zacks)
Jan-11-24 08:48AM	Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick (Zacks)
Jan-08-24 07:00AM	Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene (Business Wire)
Jan-03-24 11:03PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals (GuruFocus.com) -9.95%
Dec-19-23 07:27AM	Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +30.93%
Dec-07-23 09:44AM	Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene (Zacks) +15.92%
Dec-06-23 07:00AM	Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine (Business Wire) +42.55%
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-21-23 07:30AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
Nov-15-23 01:08PM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript (Insider Monkey) +11.76%
Nov-14-23 07:30AM	Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-23 07:30AM	Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire) +5.36%
Oct-02-23 08:45AM	Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company (Business Wire) -18.73%
Sep-07-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 09:49PM	Q2 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Aug-04-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Aug-01-23 07:30AM	Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-27-23 06:29AM	The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet (American City Business Journals)
Jul-21-23 05:40PM	Pfizer to end license deal with Syros for blood disorder therapies (Reuters)
Jul-05-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-22-23 08:14PM	Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Jun-13-23 08:00AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-08-23 07:30AM	Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference (Business Wire)
Jun-01-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-25-23 05:05PM	Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting (Business Wire) -5.06%
08:44AM	One Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \ (Simply Wall St.)
May-13-23 10:15AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 10:08PM	Q1 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +10.29%
08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
May-09-23 07:00AM	Syros to Present at JMP Securities 2023 Life Sciences Conference (Business Wire)
May-07-23 08:40PM	ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? (Zacks)
May-03-23 07:30AM	Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 (Business Wire)
May-02-23 07:00AM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.95%
Mar-06-23 09:48AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 07:08AM	Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Mar-02-23 10:02PM	Q4 2022 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (Business Wire)
Feb-28-23 07:30AM	Syros to Participate in Upcoming Investor Conferences in March (Business Wire)
Feb-23-23 07:30AM	Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 (Business Wire)
Feb-09-23 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.61%
Feb-01-23 09:43AM	Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jan-26-23 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome (Business Wire)
Jan-09-23 07:00AM	Syros Announces Clinical Updates and 2023 Strategic Priorities (Business Wire)
Dec-23-22 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-16-22 06:47AM	One Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider upped their stake by 212% in the previous year (Simply Wall St.) -7.73%
Dec-12-22 07:30AM	Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS (Business Wire) +5.04%
Dec-10-22 10:00AM	Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial (Business Wire)
Dec-05-22 07:00AM	Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 (Business Wire)

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fanucci Marsha	Director	Mar 14 '25	Proposed Sale	0.10	9,333	924		Mar 14 04:43 PM
WIRTH PETER	Director	Mar 11 '25	Proposed Sale	0.22	9,333	2,008		Mar 11 05:46 PM
Flagship Pioneering Fund VII,	Affiliate	Dec 27 '24	Proposed Sale	0.24	1,135,308	272,474		Jan 16 04:49 PM
AKKARAJU SRINIVAS	Director	Dec 30 '24	Proposed Sale	0.25	9,333	2,306		Dec 30 05:11 PM
Flagship Pioneering Fund VII,	Affiliate	Dec 27 '24	Proposed Sale	0.21	1,331,624	279,641		Dec 27 04:02 PM
Flagship VentureLabs IV LLC	Affiliate	Dec 13 '24	Proposed Sale	0.23	21,333	4,907		Dec 13 04:17 PM
Flagship Pioneering Fund VII,	Affiliate	Dec 13 '24	Proposed Sale	0.23	1,000,000	230,000		Dec 13 04:09 PM
Flagship Ventures Fund IV-RX,	Affiliate	Dec 13 '24	Proposed Sale	0.23	55,925	12,863		Dec 13 04:08 PM
Flagship Ventures Fund IV, LP	Affiliate	Dec 13 '24	Proposed Sale	0.23	216,590	49,816		Dec 13 04:07 PM
Richard Young	Director	Dec 10 '24	Proposed Sale	0.23	6,667	1,533		Dec 10 03:01 PM
Simonian Nancy A	Director	Dec 02 '24	Sale	0.27	37,070	10,016	4,000	Dec 04 05:00 PM
Nancy Cole	Director	Dec 02 '24	Proposed Sale	0.27	37,070	10,016		Dec 02 05:07 PM
Simonian Nancy A	Director	Nov 25 '24	Sale	0.27	134,713	35,739	41,070	Nov 27 05:00 PM
Simonian Nancy A	Director	Nov 25 '24	Proposed Sale	0.20	134,713	26,943		Nov 25 05:59 PM
Stephens Kristin	Chief Development Officer	Nov 18 '24	Sale	0.22	36,133	7,949	0	Nov 20 05:00 PM
Roth David	Chief Medical Officer	Nov 18 '24	Sale	0.20	12,099	2,382	0	Nov 20 05:00 PM
Quirk Gerald E	Chief Legal & Compliance Offic	Nov 19 '24	Sale	0.22	46,657	10,321	0	Nov 20 05:00 PM
Chee Conley	President & CEO	Nov 18 '24	Sale	0.20	134,797	26,932	0	Nov 20 05:00 PM
Haas Jason	Chief Financial Officer	Nov 18 '24	Sale	0.21	137,803	28,980	0	Nov 20 05:00 PM
Quirk Gerald E	Officer	Nov 19 '24	Proposed Sale	0.22	46,657	10,323		Nov 19 05:22 PM
Haas Jason	Officer	Nov 18 '24	Proposed Sale	0.23	37,803	8,669		Nov 18 06:00 PM
Roth David	Officer	Nov 18 '24	Proposed Sale	0.20	12,099	2,382		Nov 18 05:42 PM
Stephens Kristin	Officer	Nov 18 '24	Proposed Sale	0.22	36,133	7,949		Nov 18 05:20 PM
Chee Conley	Officer	Nov 18 '24	Proposed Sale	0.20	30,797	6,139		Nov 18 04:45 PM
JASON HAAS	Officer	Nov 18 '24	Proposed Sale	0.20	100,000	20,310		Nov 18 04:18 PM
Chee Conley	Officer	Nov 18 '24	Proposed Sale	0.26	100,000	25,930		Nov 18 12:08 PM
Chee Conley	President & CEO	Sep 11 '24	Buy	1.71	50,000	85,420	122,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 12 '24	Buy	1.68	45,344	76,006	124,552	Sep 12 05:00 PM
Chee Conley	President & CEO	Sep 10 '24	Buy	1.51	50,000	75,260	72,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 10 '24	Buy	1.55	35,363	54,788	59,915	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 11 '24	Buy	1.58	19,293	30,446	79,208	Sep 12 05:00 PM
Young Richard A	Director	Jun 28 '24	Sale	5.12	34,837	178,365	8,000	Jul 02 04:15 PM
Roth David	Chief Medical Officer	Apr 03 '24	Sale	4.95	10,451	51,732	0	Apr 05 04:30 PM
Roth David	Chief Medical Officer	Apr 02 '24	Sale	4.98	150	747	10,451	Apr 02 04:58 PM

MLYS

Mineralys Therapeutics Inc

SRRK

Scholar Rock Holding Corp

ALMS

Alumis Inc

SYRS

Syros Pharmaceuticals Inc

Upgrade your FINVIZ experience